Authors: Eaton M et al.
Anesthesiology 144(4):1029–1030, April 2026
Summary:
This reply addresses concerns raised about the use of Dabigatran with Idarucizumab for cardiopulmonary bypass (CPB) anticoagulation. The authors acknowledge the limitations highlighted in the prior commentary and emphasize that this work remains in an early, preclinical stage of development.
They agree that defining the minimum effective dose is critical for both safety and cost but note that determining this threshold is complex. Similarly, they recognize that reliable and durable reversal is essential—especially since reversibility is the main advantage of this drug pair. The pharmacokinetics of dabigatran and idarucizumab are complex and will require further investigation to ensure consistent and safe reversal in clinical settings.
The authors also concur that the experimental model lacked key real-world surgical factors, such as cardiotomy suction and surgical trauma, both of which significantly influence coagulation. They confirm that future studies are already underway to address these limitations and better simulate clinical conditions.
Importantly, the authors stress that this research is still far from clinical application. While dabigatran is already approved in oral form, the intravenous formulation used in this context is still in early development. They highlight that translating such innovations into clinical practice typically takes many years.
Overall, the reply reinforces that while the concept is promising, substantial work remains before this approach could become a viable alternative to heparin or other anticoagulants in CPB.
Key Points:
- Authors acknowledge limitations in dosing, reversal, and model design
- Reversibility remains the key advantage but requires further validation
- Pharmacokinetics of dabigatran–idarucizumab are complex
- More realistic surgical models are needed for future studies
- Clinical translation is still years away
What You Should Know:
They’re basically saying: “you’re right—and we’re working on it.” This is early-stage innovation. The concept is exciting, but it’s going to take years of work before it’s something you’d ever use in the OR.
We would like to thank Anesthesiology for allowing us to summarize and share this article.